



OBTAINING OF PRACTICE LICENCE OF MEDICAL INSTITUTION BY SINO-SINGAPORE CANCER CENTRE

1. Introduction

The Board of Directors (the “**Board**”) of TalkMed Group Limited (the “**Company**” and together with its subsidiaries and associated company, collectively the “**Group**”) refers to the Company’s announcement dated 29 August 2018 on the Entry into Collaboration Framework Agreement with the People’s Government of Yongchuan District (“**Yongchuan**”), Chongqing Municipality (“**Chongqing**”), the People’s Republic of China (the “**PRC**”), its announcement dated 13 September 2019 on the Entry into an Equity Joint Venture Contract on the Establishment of the Sino-Singapore Oncology Hospital, and its announcement dated 1 October 2019 on the establishment of Sino-Singapore Hospital Management (Chongqing) Co., Ltd. (中新医院管理(重庆)有限公司) (“**SSHM**”), the joint venture company with Chongqing Yongchuan District People’s Hospital.

2. Obtaining of practice licence of medical institution by Sino-Singapore Cancer Centre

- 2.1 As part of the Group’s plan to expand its operations to the PRC, SSHM has established Sino-Singapore Cancer Centre (“**SSCC**”), a category 2A (二级甲) oncology hospital, which is located in Yongchuan, Western Chongqing, PRC. The establishment of SSCC is part of the China-Singapore (Chongqing) Connectivity Initiative and marks the Company’s first investment in the PRC to offer the Group’s medical oncology services to cancer patients in the PRC. The Group will also be opening a medical outpatient centre in Beijing (the “**Beijing Centre**”) which is slated to open in the first half of this year 2021.
- 2.2 Operating on a gross floor area of approximately 11,000 square metres, SSCC is a 150-bed oncology hospital that will offer a comprehensive suite of services from cancer diagnosis to cancer treatment as well as post-treatment care when fully opened.
- 2.3 SSCC will house advanced equipment, including, among others, a positron emission tomography - computed tomography (PET/CT) machine and a medical linear accelerator. It will have an ambulatory treatment centre with 30 chairs to provide outpatient chemotherapy for patients.
- 2.4 The integrated care model is delivered by a multi-disciplinary team of medical doctors, nurses, counsellors and other paramedical professionals, from both the PRC and Singapore, to ensure a holistic cancer care experience for its patients.
- 2.5 The Board is pleased to announce that the refurbishment and renovation works of SSCC were completed and the practice licence of medical institution has been obtained. The commencement of SSCC’s operations is subject to other regulatory approvals which the Board will provide further updates as and when they are available.
- 2.6 The Company will also provide further updates in relation to the Beijing Centre as and when there are any material developments.



3. Financial effects

SSCC is not expected to have any material impact on the net tangible assets per share and earnings per share of the Group for the financial year ending 31 December 2021.

4. Interests of Directors and Substantial or Controlling Shareholders

None of the Directors and, to the best knowledge of the Directors, none of the substantial shareholders or controlling shareholders of the Company, has any direct or indirect interest in the investment in SSHM or SSCC.

By Order of the Board

Dr Ang Peng Tiam
Chief Executive Officer
12 April 2021

This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, Hong Leong Finance Limited. This announcement has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Kaeson Chui, Vice President, at 16 Raffles Quay, #01-05 Hong Leong Building, Singapore 048581, Telephone number: (65) 6415 9886